Clinical Trial Update: Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Efprezimod Alfa (CD24Fc, MK-7110) to reduce LDL and inflammation in HIV patients; study terminated with posted results in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias
• HIV Infections

Drugs mentioned

• Efprezimod Alfa (CD24Fc, MK-7110) (CD24Fc)

Snippet

Sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: HIV Infections, Dyslipidemias | Phase 2 | Status: TERMINATED | Results posted: 2022-06-08